Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Taysha Gene Therapies Inc. (TSHA:NASDAQ), powered by AI.
Taysha Gene Therapies Inc. is currently trading at $5.85. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Taysha Gene Therapies Inc. on Alpha Lenz.
View Taysha Gene Therapies Inc.'s valuation metrics on Alpha Lenz.
“Taysha Gene Therapies Inc.'s ROE is -68.5%. Explore profitability and growth together.”
Ask for details →Taysha Gene Therapies Inc. is a biotechnology company specializing in the development of transformative gene therapy treatments for central nervous system (CNS) diseases. The company is at the forefront of employing advanced gene therapy techniques to address rare, debilitating neurological conditions that lack effective treatment options. Taysha Gene Therapies is committed to leveraging its expertise in gene therapy to create long-term, potentially curative solutions that improve patient outcomes. It collaborates with academic institutions and utilizes strategic partnerships to facilitate the advancement and commercialization of its pipeline. Through targeted delivery systems and innovative genetic approaches, Taysha focuses on various therapeutic candidates, aiming to address a wide spectrum of CNS disorders. Positioned prominently in the biotechnology sector, the company plays a significant role in advancing the field of genetic medicine, offering hope for patients with limited options. Its contributions help to shape the future of precision medicine, marking a pivotal shift in the treatment landscape for genetic disorders.
“Taysha Gene Therapies Inc.'s ROE is -68.5%. Explore profitability and growth together.”
Ask for details →Taysha Gene Therapies Inc. (ticker: TSHA) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 73 employees.
The current price is $5.85 with a P/E ratio of -x and P/B of -x.
ROE is -68.45% and operating margin is -1130.65%. Annual revenue is $10M.